McNerney Lab

Identifying genomic changes and therapeutic vulnerabilities in blood cancer

Research overview

Over 50,000 people are diagnosed with a myeloid neoplasm every year in the U.S. alone.  A high-risk subset of these patients is unresponsive to current treatments and their survival is less than a year, a rate that has remained unchanged for the last 40 years.  The long-term goal of our work is to improve the outcome for these patients.  To accomplish this, research in the lab focuses on understanding the underlying genomic abnormalities in high-risk myeloid neoplasms, to identify new treatment options.

Functional genomics

We use a variety of next-generation approaches to decipher the cancer genome.

Selected Metrics

Team members